Non Small Cell Lung Cancer Treatment Algorithm

Approximately two thirds of patients have evidence of distant metastasis at presentation.

Non small cell lung cancer treatment algorithm.

But other factors such as a person s overall health and lung function and if the cancer cells have certain gene or protein changes can also be important. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used and that people have access to suitable palliative care and follow up. It primarily develops in older adult smokers. Systematic review and meta analysis of individual patient data from nine randomised.

Non small cell lung cancer t3 n0 stage iib bronchoscopy mediastinoscopy or endobronchial ultrasound fine needle aspiration ebus fna brain mri for symptomatic patients t1 2 n0 pulmonary function tests pathology 1 consistent with non small cell lung cancer history and physical chest x ray laboratory studies to. Small cell lung cancer sclc is an aggressive malignancy. Radiotherapy should be considered for high risk patients with stage ii disease positive or close margins lymph node involvement in the mediastinum and or extracapsular extension. Most common presenting symptoms are cough chest pain haemoptysis dyspnoea and weight loss.

Cancer treatment algorithms depict best practices for care delivery that illustrate a multidisciplinary approach for evaluating diagnosing and providing treatment recommendations and ongoing surveillance for various malignancies. Latest enhanced and revised set of guidelines. Postoperative radiotherapy in non small cell lung cancer. Surgery is potentially the most curative therapeutic option for this disease.

This guideline covers diagnosing and managing non small cell and small cell lung cancer. Treatment recommended for some patients in selected patient group. Esmo has clinical practice guidelines on the following lung and chest tumours. Early and locally advanced non small cell lung cancer metastatic non small cell lung cancer thymic epithelial tumours malignant pleural mesothelioma small cell lung cancer.

The previous standard of care in metastatic non small cell lung cancer nsclc was to treat patients with a platinum doublet for four to six cycles and to offer second line therapy upon progression the emergence of molecular testing specifically for the epidermal growth factor receptor egfr and for anaplastic lymphoma kinase alk enables us to better tailor.